BSE filing, NSE: LALPATHLAB. Summary written from the filing by ALFA Finder's alert engine.
Dr. Lal Pathlabs Ltd: key numbers
- Share price
- ₹1,922.30
- Market cap
- ₹32,266 Cr
- Revenue (annual)
- ₹2,763 Cr
- Net profit (annual)
- ₹504.8 Cr
- P/E (TTM)
- 59.5×Sector 52.0×
- Promoter holding
- 52.93%-0.26% QoQ
- FII holding
- 18.73%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Dr. Lal Pathlabs Ltd
All →Dr. Lal Pathlabs Board Meeting Date
Dr. Lal PathLabs updated its 4 November 2026 board meeting notice to add a possible second interim dividend. The meeting will also approve unaudited quarterly results.
Dr. Lal Pathlabs Acquisition Worth ₹30.3 Cr
Dr. Lal PathLabs subscribed to WOS PUPL equity to fund PUPL's buyout of remaining 30% in CentraPath Labs for ₹30.3 Crore. CentraPath becomes a wholly owned subsidiary.
- Value
- ₹30.30 Cr
Dr. Lal Pathlabs Other Announcement
Dr. Lal PathLabs submitted the quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, received from its RTA.
Dr. Lal Pathlabs Legal & Regulatory
Dr. Lal PathLabs disclosed an ITAT tax appeal against a favorable order for Rs.32.66 Crore ESOP expense relief (AY 2022-23). The company expects no material financial impact.
- Value
- ₹32.66 Cr
Dr. Lal Pathlabs Other Announcement
Dr. Lal PathLabs reported PIT disclosures for trades by designated persons and its Employee Welfare Trust, totaling approximately ₹0.83 Crore. These involved ESOP allotments and market sales.
- Value
- ₹0.09 Cr
Dr. Lal Pathlabs Acquisition Worth ₹38 Cr
Dr. Lal Path Labs' subsidiary completed the acquisition of an 80% stake in Sunshine Healthcare Limited, Ghana, for Rs.38.00 Crore. The target is now a subsidiary.
- Value
- ₹38.00 Cr
Other acquisition announcements
All →Zensar Technologies Acquisition
Zensar's board approved merging its wholly owned subsidiary M3bi India into the parent. No consideration or share issuance is involved, and NCLT sanction is pending.
ICICI Lombard General Insurance Company Acquisition Worth ₹172 Cr
ICICI Lombard disclosed that it acquired Rs.172 Crore of State Bank of India shares on October 28, 2026, in its ordinary-course investment function. Its cumulative holding in SBI is now 0.02%.
- Value
- ₹172.0 Cr
- Execution
- Investment made in multiple tranches over a period of time
Emkay Global Financial Services Acquisition Worth ₹30 Cr
Emkay Global will buy Emkay Capital Private Limited for Rs 30 Crore in cash. The related-party deal is expected to complete within 90 days.
- Value
- ₹30.00 Cr
Jindal Stainless Acquisition Worth ₹5.08 Cr
Jindal Stainless acquired an additional ~7% stake in Ampin C&I Three, taking its holding to 24.21%. The cash cost is ~₹5.08 crore for a 40 MW captive solar project.
- Value
- ₹5.08 Cr
- solar captive capacity
- 40.0 MW
OnEMI Technology Solutions Acquisition Worth ₹624.1 Cr
OnEMI Technology's board approved a Rs.624.15 Crore cash investment in Si Creva Capital Services, subscribing 23,37,516 equity shares at Rs.2,670.14 each. Completion is indicated by end-December 2026.
- Value
- ₹624.1 Cr
- Execution
- By end of December 2026
Emkay Global Financial Services Acquisition Worth ₹2.05 Cr
Emkay Capital, a subsidiary of Emkay Global, agreed to acquire Emkay Wealth Advisory for Rs. 2.05 Crore cash. The deal is an intra-group restructuring, and the target is a SEBI-registered investment adviser.
- Value
- ₹2.05 Cr
- Execution
- 90 days